Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of GTx Inc., (Nasdaq: GTXI) violated state or federal laws.
On August 19, 2013 GTx made known the results of its two Phase 3 enobosarm clinical trials in patients with non-small cell lung cancer receiving chemotherapy. The Company said the trials fell short of key goals agreed upon with the Food and Drug Administration.
GTx shares closed down 65% on the announcement.
Johnson & Weaver’s investigation will seek to determine if investors were misled based upon GTx’s previous knowledge about the drug’s effectiveness.
If you have information that could assist in this investigation, or if you are a GTx shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (
) by email or by phone at 619-230-0063, Ext. 118.
Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit